BRD4 and lymphoma: One of these inhibitors, compound 009 with balanced inhibitory activity on HDACs and BRD4 from independent binding to each enzymes exhibited the synergistic and best anti-PEL potency, while much less toxic to KSHV negative lymphomas as expected (Table 1).